Merck’s endometrial cancer therapy fails trial
The drugmaker’s Keytruda therapy in combination with chemotherapy was being evaluated in about 1,095 patients with high-risk endometrial cancer after surgery.
If you are not happy with the results below please do another search
The drugmaker’s Keytruda therapy in combination with chemotherapy was being evaluated in about 1,095 patients with high-risk endometrial cancer after surgery.
The recommendation is based on concerns that the company has not sufficiently addressed the problems and risks with the recalled devices.
Sarepta Therapeutics is anticipating full FDA approval and a label expansion for its gene therapy, Elevidys, with the company indicating on its Q1 earnings call last week that a draft label is imminent. But the therapy has come under the microscope regarding its high cost and clinical effectiveness.
Monthly medication subscription to the retailer’s virtual healthcare platform, Whole Health Rx, starts at an introductory price of $219, and does not require insurance, the company said in a statement.
Pfizer’s investigational Duchenne muscular dystrophy gene therapy fordadistrogene movaparvovec has been hit with another patient death, forcing the pharma to pause dosing in its Phase III study.
AstraZeneca announced that it will voluntarily pull Vaxzevria from the global market amid a sharp decline in demand and following the company’s recent admission that its vaccine is linked with a rare side effect.
Published: May 08, 2024 By Neil Versel BioSpace Xaira Therapeutics launched April 23 with $1 billion behind it to apply artificial intelligence to drug discovery and development. It was the largest […]
The companies hope that the drug – an under-the-skin version of a generic antipsychotic medicine called olanzapine – can be used as a once-monthly treatment for patients with the chronic mental disorder.
Today Klick Health announced the three winning entries for its first round of the $1,000,000 Klick Prize. The agency received about 200 submissions, most of which were submitted by teams, not by an individual. Round one awarded $200,000 to three teams.
CEO and founder, Christa Toole, started the company after having spent over 30 years of experience creating value for clients such as VITAS Healthcare, M&M Mars, Genentech, Novartis, Lilly and Culinary Institute of America. She also was one of the founders of Greater Than One, a media and technology agency with a focus on health care, and for the past 24 years had overseen search, social and analytics for all the agency’s clients.